Article
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
Investigational new drugs - 1 Jun 2021
How Jeffrey A, Jazaeri Amir, Westin Shannon N, Sood Anil K, Ramondetta Lois M, Xu Mingxuan, Abonofal Abdulrahman, Karp Daniel D, Subbiah Vivek, Stephen Bettzy, Rodon Jordi A, Yang Fei, Naing Aung
Abstract excerpt
Background Treatment of recurrent, unresectable granulosa cell tumor (GCT) of the ovary can be challenging. Given the rarity of the tumor, alternative therapies have been difficult to evaluate in large prospective clinical trials. Currently, to our knowledge, there are no reports of the use of immune checkpoint inhibitors in GCT patients. Here, we present a case series of GCT patients treated with pembrolizumab...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.